Familial medullary thyroid carcinoma
MONDO:0007958An instance of thyroid medullary carcinoma that is caused by an inherited modification of the individual's genome.
Also known as: medullary thyroid carcinoma, familial MTC, familial medullary thyroid carcinoma, hereditary medullary thyroid gland carcinoma, hereditary thyroid medullary carcinoma, thyroid carcinoma, familial medullary, Fmtc, MTC
2834 clinical trials for this condition and its sub-types, 23 tagged with Familial medullary thyroid carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Radioactive antibody combo targets thyroid cancer
Disease control CompletedResearchers are testing a two-step radioimmunotherapy for people with medullary thyroid cancer that has come back. Participants receive a bispecific antibody followed by a radioactive peptide. The goal is to see if this targeted radiation can shrink tumors and how safe it is.
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Which dose of vandetanib works best for thyroid cancer?
Disease control CompletedThis study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill shows promise in slowing rare thyroid cancer
Disease control CompletedThis phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many pa…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase 3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC